Placebo News and Research

RSS

The physiological relevance and effects of probable in vivo transformation of CBD to delta9-THC in humans

Researchers reviewed studies on the probable conversion of orally administered cannabidiol (CBD) to delta9-tetrahydrocannabinol (delta9-THC or THC) in humans.

10 Jun 2022

Study finds Moderna COVID vaccine efficacy peaks at 94% after 120 days

A recent research letter posted to the JAMA Network Open assessed the durability of immunity conferred by the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA)-1273 vaccine.

10 Jun 2022

The effectiveness of non-pharmacological treatments for post-viral syndromes and long COVID

A recent systematic review investigated the effectiveness of non-pharmacologic interventions for post-viral syndromes, including the post-COVID-19 syndrome.

9 Jun 2022

Analysis finds little proof that testosterone treatment increases the risk of cardiovascular events

Testosterone replacement therapy appears safe in the short-to-medium term to treat a condition caused by deficiency of the male sex hormone, according to the most comprehensive analysis of the treatment to date, published in The Lancet Healthy Longevity journal.

9 Jun 2022

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

In a recent study published in the Lancet, researchers evaluated the safety and efficacy of tixagevimab–cilgavimab, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody (mAb) combination in patients with mild to moderate coronavirus disease 2019 (COVID-19).

8 Jun 2022

Targeted dietary measures can reduce the symptom burden in allergic reactions, trial shows

Micronutrient deficiencies can promote inflammation and render the immune system particularly sensitive to allergenic substances.

8 Jun 2022

Molnupiravir reduces hospitalizations and deaths in at-risk, unvaccinated adults with COVID

In a recent phase III study published in the New England Journal of Medicine, researchers demonstrated that oral molnupiravir was effective in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapy among non-vaccinated, non-hospitalized adults at-risk for severe illness.

8 Jun 2022

Study finds added benefits of molnupiravir for non-hospitalized COVID-19 patients

In a recent investigation published in the Annals of Internal Medicine journal, scientists demonstrated the positive impacts of molnupiravir among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients and the healthcare sector apart from lowering disease-linked deaths and hospitalizations in at-risk cohorts.

7 Jun 2022

Taking everolimus post-surgery can improve outcomes in patients with high-risk renal cell carcinoma

In a study of patients with high-risk renal cell carcinoma, those who took the drug everolimus daily for up to one year after surgery lived longer without their disease returning (recurrence-free survival, or RFS) than those who did not take everolimus, although the results narrowly missed the clinical trial's prespecified level for statistical significance.

4 Jun 2022

Ibrutinib plus chemoimmunotherapy prolonged progression-free survival in previously untreated mantle cell lymphoma patients

Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society of Clinical Oncology Annual Meeting.

3 Jun 2022

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

A large randomized, placebo-controlled clinical trial led by the National Institutes of Health shows that treating adults hospitalized with COVID-19 with infliximab or abatacept - drugs widely used to treat certain autoimmune diseases - did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths.

2 Jun 2022

NIH sponsors the trial of monoclonal antibody to prevent asthma exacerbations in urban youth

The National Institutes of Health has launched a clinical trial testing whether a monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighborhoods.

2 Jun 2022

The effectiveness of nirmatrelvir therapy for preventing mortality and hospitalizations due to COVID-19 in high-risk patients during the Omicron surge

Researchers evaluated how effective nirmatrelvir is in preventing COVID-19-associated death and hospitalization in high-risk patients.

2 Jun 2022

Aromatherapy can help control pain and reduce opioid consumption, preliminary study suggests

Aromatherapy reduces post-surgical opioid use by half in hip replacement patients anxious before their operation, according to a new preliminary study being presented at the annual meeting of the European Society of Anaesthesiology and Intensive Care (ESAIC) in Milan, Italy (4-6 June).

2 Jun 2022

Newer class of antidiabetic drugs reduced risk of hospitalization for heart failure

In cardiovascular outcome trials among adults with type 2 diabetes (T2D), sodium-glucose co-transporter 2 inhibitors (SGLT-2i) have shown therapeutic promise, including reduced risk of hospitalization for heart failure compared to placebo.

1 Jun 2022

Combination bNAb therapy may offer a future alternative to daily ART for people living with HIV

Individuals with HIV who began taking antiretroviral therapy (ART) in the early stages of infection achieved a lengthy period of HIV suppression without ART after receiving two broadly neutralizing anti-HIV antibodies (bNAbs), according to a small study published today in the journal Nature.

1 Jun 2022

The effectiveness of tixagevimab/cilgavimab for prevention of SARS-CoV-2 infection and severe disease among immunocompromised patients

A recent article assessed the potency of tixagevimab/cilgavimab in averting SARS-CoV-2 infection in vaccinated immunocompromised people.

31 May 2022

Placebo News and Research

The physiological relevance and effects of probable in vivo transformation of CBD to delta9-THC in humans

Study finds Moderna COVID vaccine efficacy peaks at 94% after 120 days

The effectiveness of non-pharmacological treatments for post-viral syndromes and long COVID

Analysis finds little proof that testosterone treatment increases the risk of cardiovascular events

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

Targeted dietary measures can reduce the symptom burden in allergic reactions, trial shows

Molnupiravir reduces hospitalizations and deaths in at-risk, unvaccinated adults with COVID

Study finds added benefits of molnupiravir for non-hospitalized COVID-19 patients

Taking everolimus post-surgery can improve outcomes in patients with high-risk renal cell carcinoma

Ibrutinib plus chemoimmunotherapy prolonged progression-free survival in previously untreated mantle cell lymphoma patients

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

NIH sponsors the trial of monoclonal antibody to prevent asthma exacerbations in urban youth

The effectiveness of nirmatrelvir therapy for preventing mortality and hospitalizations due to COVID-19 in high-risk patients during the Omicron surge

Aromatherapy can help control pain and reduce opioid consumption, preliminary study suggests

Newer class of antidiabetic drugs reduced risk of hospitalization for heart failure

Combination bNAb therapy may offer a future alternative to daily ART for people living with HIV

The effectiveness of tixagevimab/cilgavimab for prevention of SARS-CoV-2 infection and severe disease among immunocompromised patients

Highest medicinal dose of cannabidiol is driver-safe, study confirms

Researchers evaluate atovaquone as a COVID-19 treatment

Vitamin D supplements have no clinically meaningful effect in people at high risk of type 2 diabetes

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News